Fluent Financial LLC Has $4.34 Million Stock Holdings in Abbott Laboratories $ABT

Key Points

• Fluent Financial LLC increased its stake in Abbott Laboratories by 43.8% during the second quarter, owning $4.34 million worth of shares, which is 1.8% of its portfolio.
• Several large investors, including Goldman Sachs and Wellington Management Group, also boosted their stakes in Abbott, resulting in institutional ownership of 75.18%.
• Abbott Laboratories announced a quarterly dividend of $0.59, translating to an annual yield of 1.8%, with the ex-dividend date set for October 15th.

Fluent Financial LLC increased its position in Abbott Laboratories (NYSE:ABT - Free Report) by 43.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,940 shares of the healthcare product maker's stock after purchasing an additional 9,723 shares during the quarter. Abbott Laboratories makes up 1.8% of Fluent Financial LLC's portfolio, making the stock its 17th biggest position. Fluent Financial LLC's holdings in Abbott Laboratories were worth $4,344,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Nuveen LLC bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at $1,658,180,000. Goldman Sachs Group Inc. grew its stake in shares of Abbott Laboratories by 29.2% during the first quarter. Goldman Sachs Group Inc. now owns 15,985,797 shares of the healthcare product maker's stock worth $2,120,516,000 after purchasing an additional 3,616,471 shares during the period. Wellington Management Group LLP increased its holdings in Abbott Laboratories by 12.8% in the first quarter. Wellington Management Group LLP now owns 29,763,415 shares of the healthcare product maker's stock valued at $3,948,117,000 after purchasing an additional 3,371,113 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Abbott Laboratories by 12.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 14,451,305 shares of the healthcare product maker's stock valued at $1,916,966,000 after buying an additional 1,639,954 shares during the period. Finally, Jensen Investment Management Inc. boosted its holdings in Abbott Laboratories by 1,221.2% during the first quarter. Jensen Investment Management Inc. now owns 1,365,785 shares of the healthcare product maker's stock worth $181,171,000 after buying an additional 1,262,407 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares of the company's stock, valued at $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.46% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. BTIG Research cut their price target on shares of Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a research report on Friday, July 18th. Leerink Partnrs raised shares of Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. Jefferies Financial Group upgraded shares of Abbott Laboratories from a "hold" rating to a "buy" rating and upped their price objective for the company from $143.00 to $145.00 in a research report on Friday, July 18th. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Abbott Laboratories in a research note on Wednesday. Finally, Leerink Partners began coverage on Abbott Laboratories in a research note on Monday, June 16th. They issued a "market perform" rating and a $143.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories has a consensus rating of "Moderate Buy" and a consensus price target of $146.24.

Abbott Laboratories Stock Up 1.1%

NYSE:ABT opened at $134.45 on Thursday. The stock has a 50-day simple moving average of $132.30 and a 200 day simple moving average of $131.48. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a market cap of $234.00 billion, a PE ratio of 16.85, a PEG ratio of 2.52 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting analysts' consensus estimates of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business's revenue was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories's payout ratio is presently 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.